TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07848295: A Phase 1, Multicenter, Open-label, Study of BMS-986527, Healthy Donor Allogeneic CD70-targeted Chimeric Antigen Receptor (CAR) T Cells, as Monotherapy or in Novel Combinations in Participants With Clear Cell Renal Cell

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 112 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$7,100,016

Rescue Site Savings

+$4,680,984

Unlock Full NCT07848295 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07848295 Rescue Dossier →